FCGR3A and neoplasm: Although the FCGR3A-158 V-F polymorphism impacts multiple autoimmune and infectious diseases and affects the response of monoclonal therapy (mAb) in some tumor patients, there is insufficient scientific evidence regarding the pathogenic role of FCGR3A in diverse cancers and whether FCGR3A functions in the immune microenvironment of different tumors through certain common molecular mechanisms.